Navigation Links
Trial seeks 'genetic fingerprint' for predicting drug effectiveness
Date:10/3/2007

etic factors that must be addressed individually.

The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.

Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.

Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.

After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.

Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. NIAID Initiates Trial of Experimental Avian Flu Vaccine
3. International trial of two microbicides begins
4. Bird Brains Show How Trial and Error May Contribute to Learning
5. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
6. HIV vaccine trial breaks ground for future research
7. Roche clinical trial registry and results database launched
8. NIAID begins clinical trial of West Nile virus vaccine
9. EuroVacc 02 HIV Vaccine Trial Begins
10. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
11. Compound might defeat African sleeping sickness, clinical trial beginning this month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2
... University of Exeter has highlighted the problems of ... Published online in the journal Biological Conservation, the ... carnivores that are released into their natural habitats. ... survives in the wild, with most deaths related ...
... NEW YORK, January 20, 2008A landmark genetic study has ... or lupus, a debilitating autoimmune disease that affects an ... the joints, kidneys, heart, lungs, brain and blood and ... Women are nine times more likely than men to ...
... the Tenovus Centre for Cancer Research at Cardiff University ... could help save the lives of women who become ... While drugs such as tamoxifen have been a huge ... of sufferers the drugs either fail to work, or ...
Cached Biology News:Captive carnivores not up to wild living 2Steps toward Stopping Autoimmune Disease 2Further breakthroughs for breast cancer patients 2
(Date:10/2/2014)... The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama's BRAIN (Brain Research through ... to revolutionize our understanding of the human mind ...
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... India , October 2, 2014 ... showcased its biometrics capabilities at the prestigious Annual Conference ... in Las Vegas , where they ... presented on varied topics like ,data analytics to support ... / registry studies, and ,benefits of working together as ...
(Date:10/1/2014)... Oct. 1, 2014  Discovery Laboratories, Inc. (Nasdaq: ... awarded a Phase II Small Business Innovation Research ... from the National Institute of Allergy and Infectious ... (NIH) to support the development of the Company,s ... countermeasure to mitigate acute and chronic/late-phase radiation-induced lung ...
Breaking Biology Technology:NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
... , , , ... Pervasis Therapeutics, Inc. today announced that it completed the ... financing. The proceeds will be used primarily to support ... biologically active therapy designed to reestablish healthy vasculature following ...
... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
Cached Biology Technology:BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4